Biogen is set for big gains on slate of trial data releases, JPMorgan says
Biogen will release data from clinical trials for a few of its investigational treatments over the next few months, which should boost its shares, per JPMorgan.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.